1Braun J. Therapy for ankylosing spondylitis: new therapeutic modalities. Best Pract Res Clin Rheumatol, 2002,16(4):631
2Huang F, Gu J, Zhao W et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum (Arthritis Care Res), 2002,47(3):249
3Baeten D, Van Damme N, Van den Bosch F et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNF-α. Ann Rheum Dis, 2001,60(8):750
4Zou JX, Rudwaleit M, Thiel A et al. Down-regulation of the non-specific and antigen-specific T cell cytokine response in ankylosing spondylitis after treatment with Infliximab. Arthritis Rheum, 2001, 44(9s):S236
5Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet, 2002,359:1187
6Gorman J, Sack K, Davis J. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med, 2002, 346(18) :1349
7Davis J, Huang F, Maksymowych WP. New therapies for ankylosing spondylitis: etanercept, thalidomide and pamidronate. Rheum Dis Clin North Am, 2003, 29(3):501
8Chan J, Villarreal G, Jin W et al. Intra-articular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther, 2002, 6(6):727
9Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Ther, 2003, 10:902
4Astrom AK,Jin D, lmamura T, et al. Current concepts growth factors in bone. lnt Orthop, 1998,22:410-416.
5Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signaling pathways converge on the TGF-beta family mediator Smadl. Nature, 1997,389 : 618-622.
6Locombe D,Toutain A, Gorlin RJ. Clinical identification of a human equivalent to the short ear murinepheno type.Ann Genet, 1994,37:184-191.
7Semonin O, Fontai D, Aviaud C, et al. Identification of three novel mutations of the noggin gene in patients with fibrodysplasia ossificans progressive. Am J Med Genet,2001,102 : 314-317.
8Lanchoney TF, Olmsted EA, Shore EM, et al. Characterization of bone morphogenetic protein 4 receptor in fibrodysplasia ossificans progressive. Clin Orthop, 1998,346 : 38-45.
9Virdi AS, Cook LJ, Oreffo RO, et al. Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Cell Mol Biol, 1998,44:1237-1246.
10Yonemori K, lrnamura T, lshidou Y, et al. Bone morphogenetic protein receptors and activin receptors are highly expressed in ossified ligament tissues of patients with ossification of the posterior longitudinal ligament. Am J Pathol, 1997,150:1335-1347.
